The Ride to Conquer Cancer Presented by Wheaton Precious Metals™ benefiting the BC Cancer Foundation is a unique, two-day cycling event to take place on August 24 and 25, 2019, journeying over 200km through BC. The Ride is a bold endeavor to Conquer Cancer. The money raised for The Ride to Conquer Cancer will benefit the BC Cancer Foundation, supporting breakthrough research and enhancements to care at BC Cancer.
RIDE TO CONQUER CANCER PARTNERS WITH LOUIS GARNEAU AS THE OFFICIAL CYCLING APPAREL SPONSOR
December 12, 2019
A leader in the cycling community joins forces with Canada’s largest peer-to-peer fundraising event
FOR IMMEDIATE RELEASE:
VANCOUVER, DECEMBER 12, 2018 – The Ride to Conquer Cancer announces Garneau as the Official Cycling Apparel Sponsor for the Canadian national event series. Thousands of participants in British Columbia, Alberta, Ontario and Quebec will take on the bold challenge of cycling over 200-kilometres in two days for cancer research and treatment. They will be united in Louis Garneau top-quality jerseys to empower them during their cycling challenge.
For 35 years, Garneau has been involved in initiatives that give back to the cycling community and bring people together. The leading manufacturer will continue their mission by partnering with the Ride to Conquer Cancer this year.
“We are proud to support events that rally so many cyclists across Canada pedaling in the fight to end cancer. Never Give Up is our motto at Garneau and we will embody this message every step of the way in this partnership,” says Michael Britten, Sales Director, Garneau.”
“The Ride is made up of a large and passionate community of cyclists that comes together every year to advance cancer research,” says Lindsay Carswell, Director of the Ride to Conquer Cancer at the BC Cancer Foundation. “It is delightful to be partnering with Garneau, a company that has a similar commitment to innovation and fuelled by a deep-rooted desire to bring people together.”
Since 2008, the event has raised more than $421 million nationwide.
About The Ride to Conquer CancerTM
The Ride to Conquer Cancer is a unique, two-day cycling event, journeying over 200-kilometres through British Columbia, Alberta, Ontario and Quebec. The Ride is a bold endeavour to conquer cancer in our lifetime. The money raised for The Ride benefits world-class institutions across the country, supporting healthcare professionals whose search for new discoveries and improved patient outcomes will have a real impact in communities, across Canada and around the world. Since 2008, the Ride to Conquer Cancer event series has raised nearly $421 million for partners in Canada.
Garneau was founded in 1983, and like so many others successful companies such as Apple, Microsoft, HP, Google, Amazon, not to mention innumerable rock bands, the company had its first headquarters in Louis’ father’s garage. Today, Garneau is an industry leader in cycling and triathlon apparel, helmets, shoes, bikes as well as nordic apparel, accessories, snowshoes and nutrition. The products we design represent our technological expertise and innovative engineering well and push back the limits of what is established in sports.
Garneau sets benchmarks for technology and performance in the industry and transforms intuitive ideas into intelligent products. Our products are tested and used by some of the best athletes in the world including Lionel Sanders, Team Rwanda, and Cycling Canada. We have indeed come a long way since Louis’ debut in the family’s garage!
THE RIDE TO CONQUER CANCER PRESENTED BY WHEATON PRECIOUS METALS ANNOUNCES $10.6 MILLION RAISED IN 10th ANNUAL EVENT
B.C.’s largest fundraiser draws over 2,500 riders, to advance cancer care for the people of B.C.
FOR IMMEDIATE RELEASE:
VANCOUVER, August 25, 2018 – The Ride to Conquer Cancer presented by Wheaton Precious Metals announced over 2,500 riders raised $10.6 million for the BC Cancer Foundation as the 10th annual Ride commenced in Cloverdale on Saturday. In 10 years, the BC Ride has raised over $96 million to support more than 47 world-leading research projects underway at BC Cancer, advancing care and providing hope to the 77,000 people facing cancer across British Columbia.
“Over 10 epic years the Ride to Conquer Cancer has been changing outcomes for British Columbians facing cancer. The Ride and its thousands of participants, tens of thousands of donors, gives families hope that together we can conquer this disease. We Ride and raise funds honouring the loved ones we’ve lost and with confidence that we’re giving the incredible scientists and clinicians at BC Cancer the power to save lives,” said Sarah Roth, President and CEO, BC Cancer Foundation.
We have been amazed by the Ride’s impact in 10 years and thank all riders, donors, crew, volunteers, sponsors and supporters, for your commitment and contribution as we pedal to break down cancer and change the outcome,” added Roth.
The annual event sees thousands of cancer survivors, cyclists and supporters come together to participate in the two-day, over 200-kilometre journey. New to 2018 and for the first-time in the Ride’s 10-year history, an all-BC route, which offered participants a cycling experience through the scenic Fraser Valley and welcomed first-time local participants and partners. Participants started in Vancouver and will end in Hope on Sunday afternoon, where family and friends will cheer them across the finish line.
“My daughter Emma was diagnosed with brain cancer in July of 2016 at the age of three. There are no words to describe the impact that a cancer diagnosis can have on a person but seeing a loved one going through it, seemed even worse to me,” said Adam Radziminski, second-year Rider from Burnaby, BC.
“A few months later she was discharged from the hospital only to be re-diagnosed six months later. She lost her battle to cancer in the spring of 2018. Despite the hardships of the traumatic experience my wife and I continue to carry-on for our son and in the memory of our lovely daughter who even on the worse days kept smiling. Emma and I shared a love for biking and her joy seeing me crossing the finish line of my first ride in 2017 will forever stay with me. My Ride journey began and will continue in order to make a positive impact in the lives of others and to honor my daughter Emma who will continue to inspire me with her courage and unbreakable spirit in the fight against cancer,” concluded Radziminski.
Wheaton Precious Metals became the presenting sponsor of the Ride to Conquer Cancer in 2014. Their team The Silver Bullets has raised a total over $1 million in nine years. Sponsorship funds donated by Wheaton Precious Metals are critical and enable funds raised by Ride participants to directly support the world-leading work of experts at BC Cancer.
“Wheaton Precious Metals is incredibly proud to sponsor this outstanding event and we congratulate everyone involved in the success of the Ride’s 10th year,” said Randy Smallwood, President and CEO of Wheaton Precious Metals and captain of The Silver Bullets.
“We all have a personal connection to cancer and by getting on our bikes to raise crucial dollars to support ground-breaking research, we continue to witness breakthroughs that are saving lives every day. Wheaton Precious Metals is committed to doing our part in the efforts to conquer cancer and we hope you will join us in 2019,” Smallwood added.
The 11th annual Ride will take place August 24 and 25, and encourages people of all athletic abilities to participate. To register for the 11th annual Ride visit www.conquercancer.ca or call (888) 771-BIKE.
MEDIA FACT SHEET
ABOUT THE RIDE
The Ride to Conquer Cancer® presented by Wheaton Precious Metals® is a unique, two-day cycling event to take place on August 24-25, 2019, journeying over 200km throughout British Columbia. Our mission is clear – a world free from cancer. The money raised for The Ride to Conquer Cancer will benefit the BC Cancer Foundation, supporting breakthrough research and enhancements to care at BC Cancer. Funds raised ensure researchers and clinicians at BC Cancer have the support needed to re- invent the standard of cancer care through leading-edge research.